These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 19274450)

  • 1. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus.
    Lutgers HL; Gerrits EG; Graaff R; Links TP; Sluiter WJ; Gans RO; Bilo HJ; Smit AJ
    Diabetologia; 2009 May; 52(5):789-97. PubMed ID: 19274450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2 diabetes.
    Tanaka K; Tani Y; Asai J; Nemoto F; Kusano Y; Suzuki H; Hayashi Y; Asahi K; Nakayama M; Miyata T; Watanabe T
    Diabet Med; 2012 Apr; 29(4):492-500. PubMed ID: 21916970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study.
    Guzder RN; Gatling W; Mullee MA; Mehta RL; Byrne CD
    Diabet Med; 2005 May; 22(5):554-62. PubMed ID: 15842509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening: The Maastricht Study.
    van Eupen MG; Schram MT; van Sloten TT; Scheijen J; Sep SJ; van der Kallen CJ; Dagnelie PC; Koster A; Schaper N; Henry RM; Kroon AA; Smit AJ; Stehouwer CD; Schalkwijk CG
    Hypertension; 2016 Oct; 68(4):956-63. PubMed ID: 27550921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.
    Noordzij MJ; Mulder DJ; Oomen PH; Brouwer T; Jager J; Castro Cabezas M; Lefrandt JD; Smit AJ
    Diabet Med; 2012 Dec; 29(12):1556-61. PubMed ID: 22937960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort.
    Keng MJ; Leal J; Mafham M; Bowman L; Armitage J; Mihaylova B
    Value Health; 2022 Mar; 25(3):435-442. PubMed ID: 35227456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86).
    Maddaloni E; Coleman RL; Agbaje O; Buzzetti R; Holman RR
    Lancet Diabetes Endocrinol; 2020 Mar; 8(3):206-215. PubMed ID: 32032540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derivation and external validation of a risk prediction algorithm to estimate future risk of cardiovascular death among patients with type 2 diabetes and incident diabetic nephropathy: prospective cohort study.
    Yu D; Shang J; Cai Y; Wang Z; Zhang X; Zhao B; Zhao Z; Simmons D
    BMJ Open Diabetes Res Care; 2019; 7(1):e000735. PubMed ID: 31798896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk assessment in type 2 diabetes mellitus: comparison of the World Health Organization/International Society of Hypertension risk prediction charts versus UK Prospective Diabetes Study risk engine.
    Herath HM; Weerarathna TP; Umesha D
    Vasc Health Risk Manag; 2015; 11():583-9. PubMed ID: 26622181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin autofluorescence (a marker for advanced glycation end products) and erectile dysfunction in diabetes.
    Kouidrat Y; Zaitouni A; Amad A; Diouf M; Desailloud R; Loas G; Lalau JD
    J Diabetes Complications; 2017 Jan; 31(1):108-113. PubMed ID: 27847146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study.
    Davis WA; Colagiuri S; Davis TM
    Med J Aust; 2009 Feb; 190(4):180-4. PubMed ID: 19220181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the Basque Country Prospective Complications and Mortality Study risk engine (BASCORE).
    Piniés JA; González-Carril F; Arteagoitia JM; Irigoien I; Altzibar JM; Rodriguez-Murua JL; Echevarriarteun L;
    Diabetologia; 2014 Nov; 57(11):2324-33. PubMed ID: 25212259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
    Bonora E; Bryzinski B; Hirshberg B; Cook W
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):374-9. PubMed ID: 27033025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes.
    Boersma HE; van Waateringe RP; van der Klauw MM; Graaff R; Paterson AD; Smit AJ; Wolffenbuttel BHR
    BMC Endocr Disord; 2021 Jan; 21(1):14. PubMed ID: 33435948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes.
    van Dieren S; Peelen LM; Nöthlings U; van der Schouw YT; Rutten GE; Spijkerman AM; van der A DL; Sluik D; Boeing H; Moons KG; Beulens JW
    Diabetologia; 2011 Feb; 54(2):264-70. PubMed ID: 21076956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding pharmacists to primary care teams reduces predicted long-term risk of cardiovascular events in type 2 diabetic patients without established cardiovascular disease: results from a randomized trial.
    Ladhani NN; Majumdar SR; Johnson JA; Tsuyuki RT; Lewanczuk RZ; Spooner R; Simpson SH
    Diabet Med; 2012 Nov; 29(11):1433-9. PubMed ID: 22486226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction.
    Januszewski AS; Sachithanandan N; Karschimkus C; O'Neal DN; Yeung CK; Alkatib N; Jenkins AJ
    Diabet Med; 2012 Jun; 29(6):726-33. PubMed ID: 22211881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin autofluorescence and complications of diabetes: does ethnic background or skin color matter?
    Ahdi M; Gerdes VE; Graaff R; Kuipers S; Smit AJ; Meesters EW
    Diabetes Technol Ther; 2015 Feb; 17(2):88-95. PubMed ID: 25562390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.
    Stevens RJ; Coleman RL; Adler AI; Stratton IM; Matthews DR; Holman RR
    Diabetes Care; 2004 Jan; 27(1):201-7. PubMed ID: 14693990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UKPDS Risk Engine, decode and diabetes PHD models for the estimation of cardiovascular risk in patients with diabetes.
    Almeda-Valdes P; Cuevas-Ramos D; Mehta R; Gomez-Perez FJ; Aguilar-Salinas CA
    Curr Diabetes Rev; 2010 Jan; 6(1):1-8. PubMed ID: 20034373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.